Shinsuke Yamanda

ORCID: 0000-0002-8771-844X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Disaster Response and Management
  • Lung Cancer Research Studies
  • Dysphagia Assessment and Management
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Occupational and environmental lung diseases
  • Asthma and respiratory diseases
  • Angiogenesis and VEGF in Cancer
  • Pediatric health and respiratory diseases
  • Pancreatic and Hepatic Oncology Research
  • Gastroesophageal reflux and treatments
  • Respiratory and Cough-Related Research
  • CAR-T cell therapy research
  • Respiratory Support and Mechanisms
  • Pulmonary Hypertension Research and Treatments
  • Immunotherapy and Immune Responses
  • Cancer Diagnosis and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Chronic Lymphocytic Leukemia Research
  • Stuttering Research and Treatment
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Lung Cancer Diagnosis and Treatment
  • Pleural and Pulmonary Diseases
  • Injury Epidemiology and Prevention

Sendai Kousei Hospital
2017-2024

Sendai Shakai Hoken Hospital
2020

Red Cross Hospital
2012

Tohoku University
2006-2011

Institute of Aging
2009

Furukawa Electric (Japan)
2006

Respiratory Clinical Trials
2006

Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small lung cancer (NSCLC). However, immune checkpoint inhibitors, including anti-PD-1, have not been assessed patients with subclinical disease NSCLC, and no useful clinical biomarkers associated immune-related adverse events (irAEs) among these treated anti-PD-1.To assess the safety efficacy anti-PD-1 treatment NSCLC or without preexisting autoimmune markers, rheumatoid factor,...

10.1001/jamaoncol.2018.5860 article EN JAMA Oncology 2018-12-27

Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of irAEs correlates treatment response in advanced non-small-cell lung cancer (NSCLC).We conducted a retrospective patients who received monotherapy at Sendai Kousei Hospital (n = 70). The were categorized into two groups based on incidence irAEs: those (irAE group) or without (non-irAE group). Treatment efficacy was evaluated each group. further...

10.1634/theoncologist.2017-0384 article EN The Oncologist 2018-06-22

To investigate the efficacy and safety of nitroglycerin plus vinorelbine cisplatin in patients with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC) as experimental arm for next phase III trial.One hundred twenty NSCLC were randomly assigned to 25 mg/m2 on days 1 8 80 day 1, transdermally applied (25 mg/patient daily 5 days; A) or placebo patch (arm B) every 3 weeks a maximum four cycles double-blind controlled trial. Primary end points best confirmed response rate time...

10.1200/jco.2005.04.0436 article EN Journal of Clinical Oncology 2006-01-31

Abstract Purpose: Nitroglycerin may improve the response to chemotherapy in advanced non–small cell lung cancer. The effects and mechanisms of nitroglycerin on enhancement chemosensitivity docetaxel carboplatin regimen (DCb) patients with adenocarcinoma have not been reported. Experimental Design: Seventeen operable stable angina pectoris were selected investigate immunoreactivity for hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth (VEGF), P-glycoprotein (P-gp), production...

10.1158/1078-0432.ccr-06-1124 article EN Clinical Cancer Research 2006-11-15

To investigate the impact in an aging society of 2011 Great East Japan earthquake on hospitalisation for respiratory disease at disaster base hospital.Descriptive and cross-sectional study.Emergency care Japanese Red Cross Ishinomaki Hospital, a regional hospital Miyagi, Japan.322 emergency patients who were hospitalised from 11 March to 9 May 2011, 99 105 corresponding periods 2009 2010, respectively.Description comparison patient characteristics distribution terms age, time after...

10.1136/bmjopen-2012-000865 article EN cc-by-nc BMJ Open 2013-01-01

The clinical phenotypes and underlying mechanisms of asthma-COPD overlap syndrome (ACOS) remain elusive. This study aimed to investigate a comparison COPD patients with without ACOS, focusing on inflammatory biomarkers, in an outpatient cohort.We conducted cross-sectional analyzing prospectively collected data from the Ishinomaki Network registry. All participants were diagnosed COPD, confirmed by using spirometry, aged 40-90 years former smokers. Patients features asthma including both...

10.2147/copd.s113647 article EN cc-by-nc International Journal of COPD 2016-09-01

The effects of serotonin (5-HT) on tumor growth are inconsistent. We investigated whether a decreased level 5-HT affected using transporter knockout (5-HTT-/-) mice, which showed depletion. When cancer cells were injected subcutaneously into both 5-HTT-/- and 5-HTT+/+ the was markedly attenuated in mice. Serotonin levels blood, forebrain, tumors mice bearing significantly smaller than those their littermates. However, did not increase cells' proliferation vitro. we applied 5-HTT inhibitors...

10.1593/neo.81630 article EN cc-by-nc-nd Neoplasia 2009-04-01

Abstract Background Anti-programmed cell death 1 antibody is a standard therapy for advanced non-small lung cancer (NSCLC). However, immune-related adverse events (irAEs), such as skin reactions, are frequently observed. Although reactions associated with clinical efficacy in melanoma, this association NSCLC and predictors of irAEs remain unclear. Accordingly, study identified potential correlations development reactions. Subjects, Materials, Methods We retrospectively surveyed patients who...

10.1634/theoncologist.2019-0550 article EN The Oncologist 2019-11-07

Erythropoietin (Epo), a known hematopoietic growth factor, has been reported to promote tumor and angiogenesis in Epo receptor (EpoR)–positive tumors, but its effects on EpoR-negative tumors have not clearly shown. Here, we show that accelerates the of by promoting angiogenesis. Mice were inoculated with Lewis lung carcinoma cells treated Epo. accelerated increased intratumoral microvessel density, although it did accelerate cell proliferation vitro. To observe direct effect endothelial...

10.1593/neo.08140 article EN cc-by-nc-nd Neoplasia 2008-09-01

A large-scale natural disaster may exacerbate chronic respiratory diseases, such as obstructive pulmonary disease (COPD). The aftermath of a can include poor access to medication, medical equipment, and supplies. Little is known about the impact on patients with COPD.A retrospective cohort study was conducted at regional center in Ishinomaki, area affected most severely by Great East Japan Earthquake 2011. performed 6 months after disaster. characteristics, clinical courses, outcomes COPD...

10.1016/j.resinv.2012.10.004 article EN cc-by-nc-nd Respiratory Investigation 2012-12-27

Abstract Although the clinical value of fluoroscopically guided respiratory endoscopy (bronchoscopy) is clear, there have been very few studies on radiation dose received by staff during bronchoscopy. The International Commission Radiological Protection (ICRP) suggesting reducing occupational lens limit markedly from 150 to 20 mSv/year, averaged over defined periods five years. purpose this study was clarify current eye bronchoscopy conducting procedures. We measured doses (3-mm-dose...

10.1093/jrr/rraa034 article EN cc-by Journal of Radiation Research 2020-07-08

The down-regulation of the cough reflex in patients with aspiration pneumonia can involve both cortical facilitatory pathways for and medullary pathways. In order to study possible involvement supramedullary system reflex, we evaluated urge-to-cough pneumonia.Cough sensitivity inhaled citric acid were at least a history age-matched healthy elderly people. sensitivities defined as lowest concentration that elicited two or more coughs (C2) five (C5). scores C2 C5, times dilution (C2/2) C5...

10.1186/1745-9974-4-11 article EN cc-by Cough 2008-11-19

Abstract The incidence of cancer in patients with schizophrenia has been reported to be lower that the general population. On other hand, it is well established have a hyper‐dopaminergic system and dopamine ability inhibit tumor angiogenesis. Therefore, order investigate molecular mechanisms responsible for risk schizophrenic patients, we used mouse model schizophrenia, which shows transmission nerve terminals dopaminergic neurons. Here, hypothesized growth was reduced lacking transporter...

10.1002/ijc.23562 article EN International Journal of Cancer 2008-05-09

Purpose: The GOLD report provides a framework for classifying COPD in way that reflects its clinical impact and allows treatment recommendations. 2017 proposes new classification whereby patients are grouped as A–D according to their symptoms history of exacerbations. However, the characteristics outcomes these not well documented. Patients methods: In this prospective observational study, we analyzed data from Ishinomaki Network Registry. All with stable were classified into four groups...

10.2147/copd.s182905 article EN cc-by-nc International Journal of COPD 2018-12-01

Immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events (irAEs). A correlation between the development of irAEs and efficacy has been suggested; however, it is unclear whether there a relationship programmed death ligand 1 (PD-L1) expression these events.We performed retrospective study advanced or metastatic non-small cell lung cancer (NSCLC) patients who were treated with pembrolizumab monotherapy at our institution May 2015 April 2018 (n = 44). Patients categorized...

10.31662/jmaj.2019-0005 article EN JMA Journal 2019-01-01

The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. aim present study was to evaluate CIP clinical efficacy anti-programmed cell death-1 antibody in patients advanced non-small lung cancer (NSCLC).Between January 2016 August 2019, 203 NSCLC were administered nivolumab or pembrolizumab. Comparisons made without CIP. We evaluated time-to-treatment failure (TTF), progression-free (PFS), overall (OS).CIP...

10.1002/cam4.4045 article EN Cancer Medicine 2021-06-13

Abstract Background Anaplastic lymphoma kinase ( ALK )‐positive lung cancer has a better long‐term prognosis with ‐inhibitor than other cancers. However, resistance to ‐inhibitors and the control of metastases in central nervous system (CNS) remain be challenge management ‐positive cancer. Case We present case 23‐year‐old man who developed multiple brain while receiving alectinib treatment for After 3 months lorlatinib initiation, disappeared, complete response (CR) was maintained....

10.1002/cnr2.1981 article EN cc-by Cancer Reports 2024-01-11

ABSTRACT Background The expansion of preoperative immunochemotherapy has led to an increase in the number patients with lung cancer receiving immune checkpoint inhibitors (ICIs). Therefore, oncologists should manage a variety immune‐related adverse events (irAEs). One rare, life‐threatening, and recently proposed irAEs is cytokine release syndrome (CRS). Although standard treatment irAE systemic administration steroids, it been suggested that tocilizumab may be effective option for CRS. Case...

10.1002/cnr2.2145 article EN cc-by Cancer Reports 2024-07-01

We report two cases of organizing pneumonia (OP) secondary to the inhalation dried tsunami sludge which formed during 2011 Great East Japan Earthquake and consequent tsunami. After disaster, both these patients had been engaged in restoration work. About half a month later, they developed shortness breath pulmonary infiltrates. These were diagnosed with interstitial pneumonia. Their biopsy specimens revealed multifocal peribronchiolitis OP. An electron probe microanalysis demonstrated...

10.2169/internalmedicine.55.6952 article EN Internal Medicine 2016-01-01
Coming Soon ...